Modality
Peptide
MOA
AuroraAi
Target
EZH2
Pathway
Hedgehog
PNH
Development Pipeline
Preclinical
Sep 2021
→ Apr 2028
PreclinicalCurrent
NCT04740152
1,242 pts·PNH
2021-09→2028-04·Active
1,242 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-242.1y awayInterim· PNH
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Preclinical
Active
Catalysts
Interim
2028-04-24 · 2.1y away
PNH
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04740152 | Preclinical | PNH | Active | 1242 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |